<DOC>
	<DOC>NCT02701634</DOC>
	<brief_summary>This study will evaluate the effect of entospletinib on the best overall response rate in adults with chronic graft versus host disease (cGVHD) who are currently receiving systemic corticosteroids as first-line therapy for cGVHD.</brief_summary>
	<brief_title>Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<criteria>Key Willing and able to provide written informed consent Male or nonpregnant, nonlactating, females Newly diagnosed cGVHD defined by: At least 100 days after receiving any allogeneic hematopoietic stem cell transplant AND Receiving a new course of systemic corticosteroids (≥ 0.5 mg/kg/day) as firstline cGVHD therapy at least 1 day and no more than 21 days prior to first dose of ENTO/Placebo AND Moderate to severe cGVHD as assessed by NIH cGVHD Diagnosis and Staging Criteria (NCDSC) with at least three organ systems involved OR one organ system with a score of 2 OR lung organ score = 1 Individuals who have undergone transplant for hematologic malignancy are required to be in complete remission. Have either a normal ECG or one with abnormalities that are considered clinically insignificant by the investigator in consultation with the Sponsor Key Inability to begin systemic corticosteroids therapy at a dose of ≥ 0.5 mg/kg/day (or equivalent) Uncontrolled infection within 4 weeks prior to randomization History of the following therapies in the posttransplant period: B cell depleting biologic agents CD19 CART cells based therapies BTK/SYK/JAK/PI3K inhibitors Phototherapyunless administered for acute GVHD Treatment of cGVHD with antithymocyte globulins (ATG), or campath within 60 days of screening visit unless used for treatment of acute GVHD Severe organ dysfunction manifested during screening period: Requiring supplemental oxygen at more than 2 L/min Uncontrolled arrhythmia or heart failure Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Graft Versus Host Disease (cGVHD)</keyword>
	<keyword>newly diagnosed cGVHD</keyword>
	<keyword>immune reconstitution</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
	<keyword>SYK inhibitor</keyword>
</DOC>